openPR Logo
Press release

In Depth Research on Oncogene Inhibitors Market & Pipeline Insight 2015

10-04-2017 08:08 AM CET | Health & Medicine

Press release from: Kuick Resarch

In Depth Research on Oncogene Inhibitors Market & Pipeline

" Oncogene Inhibitors Market & Pipeline Insight 2015" Report Highlight:

* Global Oncogene Inhibitors Market Overview
* Oncogene Inhibitors Pipeline by Company, Indication & Phase
* Oncogene Inhibitors Pipeline: 185 Drugs
* Majority Oncogene Inhibitors in Preclinical Phase: 105 Drugs
* Proto Oncogene Protein c met Inhibitors Pipeline: 42 Drugs
* Proto Oncogene Protein c-akt Inhibitors: 39 Drugs
* Marketed Oncogene Inhibitors: 22 Drugs
* Marketed Proto-Oncogene Protein c-bcl-2 Inhibitors: 8 Drugs

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-Oncogene-Inhibitors-Market-&-Pipeline-Insight-2015.php

Table of Contents

1. Introduction to Oncogene Inhibitors

2. Mechanism of Oncogene Inhibitors

3. Global Oncogene Inhibitors Market Overview
3.1 Current Market Scenario
3.2 Oncogene Inhibitors Clinical Pipeline Insight

4. Global Oncogene Inhibitor Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges

5. Global Oncogene Inhibitor Market Future Prospects

6. Oncogene Protein Inhibitors Pipeline by Company, Indication & Phase
6.1 Preclinical
6.2 Suspended & Discontinued

7. Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Company, Indication & Phase
7.1 Research till Preregistration
7.2 Marketed Drug Clinical Insight
7.3 Suspended & Discontinued

8. Proto Oncogene Protein b raf Inhibitors Pipeline by Company, Indication & Phase
8.1 Research till Phase-III
8.2 Marketed Drug Clinical Insight
8.3 Suspended & Discontinued

9. Proto Oncogene Protein c-kit Inhibitors Pipeline by Company, Indication & Phase
9.1 Research till Preregistration
9.2 Marketed Drug Clinical Insight
9.3 Suspended & Discontinued

10. Proto-Oncogene Protein c-rel Inhibitors Pipeline by Company, Indication & Phase
10.1 Research

11. Proto Oncogene Protein c-akt Inhibitors Pipeline by Company, Indication & Phase
11.1 Preclinical till Phase-III
11.2 Suspended & Discontinued

12. Proto Oncogene Protein c met Inhibitors Pipeline by Company, Indication & Phase
12.1 Preclinical till Phase-III
12.2 Marketed Drug Clinical Insight
12.3 Suspended & Discontinued

13. Proto Oncogene Protein c ret Inhibitors Pipeline by Company, Indication & Phase
13.1 Preclinical till Phase-III
13.2 Marketed Drug Clinical Insight
13.3 Suspended & Discontinued

14. Proto-Oncogene Protein c mdm2 Inhibitors Pipeline by Company, Indication & Phase
14.1 Preclinical till Phase-I/II
14.2 Suspended & Discontinued

15. Proto-Oncogene Protein Inhibitors Pipeline by Company, Indication & Phase
15.1 Preclinical

16. Proto-Oncogene-Protein-c-ets Inhibitors Pipeline by Company, Indication & Phase
16.1 Preclinical

17. Proto-Oncogene Protein c-fli-1 Inhibitors Pipeline by Company, Indication & Phase
17.1 Preclinical

18. Proto Oncogene Proteins c pim 1 Inhibitors Pipeline by Company, Indication & Phase
18.1 Preclinical till Phase-I/II
18.2 Suspended & Discontinued

19. Proto Oncogene Protein c-myc Inhibitors Pipeline by Company, Indication & Phase
19.1 Preclinical till Phase-I/II
19.2 Marketed Drug Clinical Insight

20. Proto Oncogene Proteins c raf Inhibitors Pipeline by Company, Indication & Phase
20.1 Suspended & Discontinued

21. Proto Oncogene Proteins c myb Inhibitors Pipeline by Company, Indication & Phase

22. Multiple Oncogene Inhibitors Pipeline by Company, Indication & Phase
22.1 Preclinical till Registered
22.2 Marketed Drug Clinical Insight
22.3 Suspended & Discontinued

23. Competitive Landscape
23.1 AstraZeneca
23.2 ArQule Inc
23.3 Biogen Idec
23.4 Boehringer Ingelheim
23.5 Celgene Corporation
23.6 Constellation Pharmaceutical
23.7 Epizyme Pharmaceutical
23.8 Genentech
23.9 GalaxoSmithKline
23.10 Incyte Corporation
23.11 Johnson & Johnson
23.12 Merck
23.13 Novartis
23.14 Onyx pharmaceuticals
23.15 Pfizer

Figure 1-1: Features of Oncogenes
Figure 1-2: Types of Genes
Figure 1-3:Factors Responsible for Conversion of Proto-Oncogenes to Oncogenes
Figure 2-1: Activation of Proto-Oncogenes to Oncogenes
Figure 2-2:Benefits of Oncogene Inhibitors
Figure 2-3: Mechanism of Crizotinib
Figure 2-4: Mechanism of Vemurafenib
Figure 2-5: Mechanism of Vorinostat
Figure 3-1: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015
Figure 3-2: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-3: Discontinued Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015
Figure 3-4: Discontinued Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-5: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(%), 2015
Figure 3-6: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(Number), 2015
Figure 3-7: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015
Figure 3-8: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015
Figure 3-9: Discontinued Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015
Figure 3-10: Discontinued Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015
Figure 3-11: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015
Figure 3-12: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015
Figure 3-13: Discontinued Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015
Figure 3-14: Discontinued Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015
Figure 3-15: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015
Figure 3-16: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015
Figure 3-17: Discontinued Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015
Figure 3-18: Discontinued Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015
Figure 3-19: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(%), 2015
Figure 3-20: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(Number), 2015
Figure 3-21: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015
Figure 3-22: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-23: Discontinued Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015
Figure 3-24: Discontinued Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-25: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(%), 2015
Figure 3-26: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-27: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(%), 2015
Figure 3-28: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(Number), 2015
Figure 3-29: Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015
Figure 3-30: Multiple Oncogene Inhibitors Pipeline by Phase(number), 2015
Figure 3-31: Discontinued Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015
Figure 3-32: : Discontinued Multiple Oncogene Inhibitors Pipeline by Phase(Number), 2015
Figure 4-1: Oncogene Inhibitor Market Favorable Parameters
Figure 4-2: Commercialization Challenges to Oncogene Inhibitors

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release In Depth Research on Oncogene Inhibitors Market & Pipeline Insight 2015 here

News-ID: 753688 • Views: 215

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases